Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine in chronic babesiosis with severe fatigue
NCT06656351Phase 2Recruiting
- Sponsor
- 60 Degrees Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafenoquine in babesiosis, sponsored by 60 Degrees Pharmaceuticals. Primary endpoint: Change in General Fatigue at 90 days. Started Nov 2025; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
babesiosis
Beyond the preview
Go deeper on NCT06656351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656351.